Hutchison Medipharma Limited
Quick facts
Phase 3 pipeline
- HMPL-306 · Oncology
HMPL-306 is a selective inhibitor of fibroblast growth factor receptor (FGFR) that blocks aberrant FGFR signaling in cancer cells. - HMPL-523 · Oncology
HMPL-523 is a selective inhibitor of focal adhesion kinase (FAK) that disrupts tumor cell adhesion and migration signaling. - Savolitinib + Osimertinib · Oncology
Savolitinib and osimertinib together target MET and EGFR pathways to overcome resistance in lung cancer. - Surufatinib plus Toripalimab · Oncology
Surufatinib inhibits multiple receptor tyrosine kinases (FGFR, VEGFR, RET) to block tumor angiogenesis and growth, while toripalimab is a PD-1 inhibitor that restores anti-tumor immune responses.
Phase 2 pipeline
Phase 1 pipeline
- [14C]Sulfatinib
- epitinib succinate
- HMPL-011 capsules
- HMPL-011 tablets
- HMPL-653
- Savolitinib Reference Preparation
- Savolitinib Test Preparation
- Sulfatinib R capsule
- Sulfatinib T capsule
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:
Frequently asked questions about Hutchison Medipharma Limited
What is Hutchison Medipharma Limited's pipeline?
Hutchison Medipharma Limited has 4 drugs in Phase 3, 3 in Phase 2, 9 in Phase 1. Late-stage candidates include HMPL-306, HMPL-523, Savolitinib + Osimertinib, Surufatinib plus Toripalimab.
Related
- Sector hub: All tracked pharma companies